The Novel Use of Mitraclip in a Patient with Combined Multiple Myeloma and Heart Failure with Severe Mitral Regurgitation

Case Report

Austin Cardio & Cardiovasc Case Rep. 2021; 6(1): 1039.

The Novel Use of Mitraclip in a Patient with Combined Multiple Myeloma and Heart Failure with Severe Mitral Regurgitation

Abu Ghosh Z*, Beeri R, Falah B, Pertz A, Shuvy M and Gilon D

Heart Institute, Hadassah - Hebrew University Medical Center, Hadassah, Ein-Kerem, Jerusalem, Israel

*Corresponding author: Zahi Abu Ghosh, Hadassah Medical Center, Cardiology Department, Heart Institute, Hadassah - Hebrew University Medical Center, Kiryat Hadassah, POB 12000, Jerusalem, Israel

Received: July 19, 2021; Accepted: August 10, 2021; Published: August 17, 2021

Abstract

Oncology patients with Heart Failure (HF) and severe Mitral Regurgitation (MR) are often considered to have a prohibitive risk for surgical mitral valve repair/replacement.

We describe a patient with active multiple myeloma and significant HF and MR who was treated with MitraClip, which improved symptoms and allowed delivery of optimal oncological treatment.

Keywords: Heart failure; Mitral regurgitation; Mitral valve repair; MitraClip; Cardio-oncology

Abbreviations

HF: Heart Failure; MR: Mitral Regurgitation; LV: Left Ventricle; MM: Multiple Myeloma; TEE: Transthoracic Echocardiography; LVEF: Left Ventricular Ejection Fraction; RVSP: Right Ventricular Systolic Pressure; TEE: Transesophageal Echocardiography

Introduction

Approximately 1.8 million new cancer cases and over 600,000 cancer deaths were reported in the U.S. in 2019 [1], with 10% having co-morbid HF. This impacts survival and is associated with increased health care costs [2-4]. Patients with HF are less likely to receive or complete chemotherapy [3]. Secondary mitral regurgitation is a common pathology among patients with HF. It occurs in up to onefourth of patients with HF with reduced ejection fraction, in which Left Ventricular (LV) dilatation induces apical tethering of the mitral leaflets with incomplete closure. MR in these patients is associated with increased mortality [5]. Many of these patients, especially those treated for cancer, have a prohibitive risk for surgical mitral valve repair/replacement. Often, severe MR inducing symptomatic HF may prevent delivery of potentially cardiotoxic chemotherapy, and complicate fluid management with other cancer treatments. This specific subgroup of patients with cancer and severe secondary MR aggravating HF, could benefit from percutaneous edge-to-edge mitral valve repair (MitraClip).

Learning Objectives

The objectives of this paper are:

• Highlight the concept that MitraClip treatment of patients with active neoplastic disease with HF and severe MR could improve symptoms and allow completing planned anti-cancer treatment.

• Demonstrating that active cancer should not be a reason to be excluded from novel interventional treatment such as MitraClip.

Case Presentation

A 83 year-old male with history of Multiple Myeloma (MM) with lambda light chain paraproteinemia, and long standing hypertension and ischemic heart disease, was admitted with acute HF exacerbation with pulmonary congestion and peripheral edema. The cardiovascular symptoms were significant enough to consider discontinuation of his anti-cancer therapy. The patient’s previous treatment included melphalan, prednisolone and thalidomide (MPT), as well as radiation for a tumor mass in the right clavicle. Following two years the treatment was switched to lenalidomide, after which he entered remission. There was relapse of the MM three months prior the present admission to our department, and bortezomib and daratumumab were initiated.

Investigations

The patient did not have chest pain, the electrocardiogram did not show ischemic changes, and laboratory work up did not show significant elevations in cardiac biomarkers. Transthoracic Echocardiography (TTE) showed mildly reduced systolic LV function with a Left Ventricular Ejection Fraction (LVEF) of 50%, and severe MR causing severe pulmonary hypertension, estimated Right Ventricular Systolic Pressure (RVSP) (81mmHg), with no mitral stenosis (Figure 1). Transesophageal Echocardiography (TEE) showed mild thickening of the mitral leaflets, mild mitral annular calcification, and incomplete closure of the mitral leaflets due to apical tethering.

Citation: Abu Ghosh Z, Beeri R, Falah B, Pertz A, Shuvy M and Gilon D. The Novel Use of Mitraclip in a Patient with Combined Multiple Myeloma and Heart Failure with Severe Mitral Regurgitation. Austin Cardio & Cardiovasc Case Rep. 2021; 6(1): 1039.